A New Glaucoma Drug Is Approaching FDA Approval — Can It Lower Eye Pressure Better Than Today's Best Drops?

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-drug-is-approaching-fda-approval-can-it-lower-eye-pressure-better-than-today-s-best-dropsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:A New Glaucoma Drug Is Approaching FDA Approval — Can It Lower Eye Pressure Better Than Today’s Best Drops? Evidence reviewed through September 10, 2026 Bottom line NCX 470—now called K-911, with the proposed generic name bimatoprost grenod—has been accepted for Food and Drug Administration review. The New Drug Application was submitted by Kowa on June 30, 2026, accepted for review on August 27, 2026, and assigned a Prescription Drug User Fee Act decision date of April 30, 2027. It is not yet approved. Kowa FDA acceptance announcement () The clinical evidence shows that NCX 470: Lowers intraocular pressure by approximately 8 to 10 millimeters of mercury in patients starting with pressures around 26 to 28 millimeters of mercury. Produces roughly 0.5 to 0.8 millimeters of mercury more reduction than latanoprost in the strongest published phase 3 dataset. Performs better than latanoprost at several individual time points, but the average advantage is modest rather than dramatic. Has more conjunctival hyperemia, or eye redness, than latanoprost. Has not been directly compared with bimatoprost, latanoprostene bunod, Rocklatan, or Cosopt in a pivotal head-to-head trial. Has not been adequately studied in patients starting with pressures in the mid-teens or in patients who need targets near 10 to 12 millimeters of mercury. My overall judgment: NCX 470 appears to be a meaningful incremental improvement over latanoprost, but not a breakthrough that is likely to replace combination therapy, selective laser trabeculoplasty, or glaucoma surgery. --- Current regulatory status For the full table, please open this article on visualfieldtest.com. FDA acceptance means the application was considered complete enough for formal review. It does not mean that approval is guaranteed. Kowa product pipeline Kowa FDA announcement () The application is supported principally by the MONT BLANC and DENALI phase 3 trials. A small phase 3b study called WHISTLER examined the drug’s effect on aqueous humor outflow but was exploratory and was not required for the New Drug Application. Nicox pre-New Drug Application update () --- What is NCX 470? NCX 470 is a nitric-oxide-donating version of bimatoprost. After the molecule is exposed to esterases in the eye, it releases: Bimatoprost-related prostaglandin activity, which primarily increases uveoscleral outflow. Nitric oxide, which is intended to relax the trabecular meshwork and improve drainage through the conventional trabecular meshwork–Schlemm canal pathway. In simplified terms: Bimatoprost helps fluid leave through the uveoscleral route. Nitric oxide attempts to improve the eye’s conventional drainage system. This is conceptually similar to latanoprostene bunod, marketed as Vyzulta, which combines a prostaglandin effect with nitric oxide donation. The difference is that Vyzulta releases a latanoprost-derived prostaglandin, whereas NCX 470 releases bimatoprost-related activity. NCX 470 mechanism and preclinical research MONT BLANC publication () --- The pivotal clinical trials MONT BLANC phase 3 trial The MONT BLANC study was a randomized, double-masked, multicenter phase 3 trial conducted at 56 United States sites and one site in China. A total of 691 patients were randomized. MONT BLANC publication ClinicalTrials.gov record () Treatment groups NCX 470 0.065%, once daily NCX 470 0.1%, once daily Latanoprost 0.005%, once daily The 0.065% arm included 30 initial patients and was stopped after the planned interim analysis. The final efficacy comparison involved: NCX 470 0.1%: 328 patients Latanoprost 0.005%: 333 patients The drops were administered to both eyes, generally in the evening. Baseline intraocular pressure The final treatment groups had very similar baseline values: For the full table, please open this article on visualfieldtest.com. These patients had relatively high baseline pressures. They were required to have untreated or washed-out pressure of at least approximately 26 millimeters of mercury at 8:00 a.m., 24 at 10:00 a.m., and 22 at 4:00 p.m. ClinicalTrials.gov results MONT BLANC responder analysis () Primary endpoint The primary endpoint was the reduction from time-matched baseline pressure at: 8:00 a.m. and 4:00 p.m. Week 2 Week 6 Month 3 The primary statistical goal was noninferiority to latanoprost. A secondary analysis examined whether NCX 470 was statistically superior. MONT BLANC: actual numerical results The table below uses the reported mean reductions from baseline. Percent reductions are calculated from the published baseline values. For the full table, please open this article on visualfieldtest.com. The reductions were statistically significant compared with baseline at every evaluated time point. NCX 470 was numerically better than latanoprost at all six time points and statistically better at four of them. ClinicalTrials.gov numerical results () Mean diurnal pressure results The secondary mean diurnal pressure analysis showed: For the full table, please open this article on visualfieldtest.com. This suggests that the average incremental benefit over latanoprost was approximately 0.5 to 0.8 millimeters of mercury, with an average across these visits of about 0.64 millimeters of mercury. That is a real difference. However, it is not the type of difference that usually transforms a patient from needing several medications to needing none. --- DENALI phase 3 trial DENALI was the second pivotal phase 3 trial. It randomized 696 patients at 90 sites in the United States and China: NCX 470 0.1%: 348 patients Latanoprost 0.005%: 348 patients Treatment was once daily in both eyes. All patients were followed through approximately six months, while a subset contributed safety data through 12 months. DENALI trial summary ClinicalTrials.gov DENALI record () Baseline pressure For the full table, please open this article on visualfieldtest.com. Reported efficacy Across the six prespecified efficacy time points: NCX 470 reduced pressure by 7.9 to 10.0 millimeters of mercury. Latanoprost reduced pressure by 7.1 to 9.8 millimeters of mercury. NCX 470 was numerically better at five of six time points. The difference favored NCX 470 by as much as 0.8 millimeters of mercury. Statistical superiority was demonstrated at three of six time points, but the overall superiority endpoint was not achieved. Thus, DENALI confirmed the general pattern seen in MONT BLANC: NCX 470 is at least as effective as latanoprost and sometimes modestly better, but the average advantage is not large. DENALI topline results () --- Comparison with other glaucoma medications Cross-trial comparisons must be interpreted cautiously. The studies used different entry pressures, populations, follow-up periods, statistical methods, and treatment schedules. A drug that appears stronger in one trial may have been tested in patients with higher starting pressure. Quantitative comparison For the full table, please open this article on visualfieldtest.com. Sources include the first-line glaucoma medication network meta-analysis, Vyzulta clinical review, ROCKET netarsudil trials, ROCKET-4, MERCURY Rocklatan pooled analysis, and fixed-combination medication meta-analysis. () NCX 470 versus latanoprost This is the best-established comparison. NCX 470 appears to provide: Approximately 0.5 to 0.8 millimeters of mercury more mean diurnal reduction in MONT BLANC. Approximately 0 to 0.8 millimeters of mercury more reduction in DENALI. A somewhat stronger morning effect, but the difference at 8:00 a.m. was inconsistent and small, ranging from 0.22 to 0.58 millimeters of mercury in MONT BLANC. The advantage is therefore statistically credible but clinically modest. NCX 470 versus bimatoprost This question is central because NCX 470 releases bimatoprost-related activity. NCX 470 has not been directly compared with marketed bimatoprost in a large pivotal human trial. A network meta-analysis of first-line drugs estimated that bimatoprost reduced pressure by approximately 5.61 millimeters of mercury, compared with 4.85 millimeters of mercury for latanoprost, a difference of approximately 0.76 millimeters of mercury. Network meta-analysis () That is important because the average NCX 470 advantage over latanoprost—roughly 0.5 to 0.8 millimeters of mercury—is similar in size to the historical advantage often reported for bimatoprost over latanoprost. Therefore, the pivotal trials do not prove that nitric oxide adds a large benefit beyond bimatoprost itself. Some of the observed difference may come from the bimatoprost component rather than the nitric oxide component. NCX 470 versus Vyzulta Vyzulta, or latanoprostene bunod, is the closest mechanistic competitor because it also combines a prostaglandin effect with nitric oxide donation. In the APOLLO and LUNAR trials: Mean baseline diurnal pressure was approximately 26.7 millimeters of mercury for latanoprostene bunod and 26.5 millimeters of mercury for timolol. Three-month mean pressure was approximately 17.8 millimeters of mercury with latanoprostene bunod and 19.1 millimeters of mercury with timolol. The implied reduction was approximately 8.9 millimeters of mercury with latanoprostene bunod, compared with approximatSupport the show